▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Mar 26, 2015 by Todd Campbell

Why Diplomat Pharmacy Inc. Is Soaring Higher Today.

After pricing its secondary offering of shares at $29 per share, Diplomat Pharmacy, Inc. shares are climbing.

Mar 26, 2015 by Todd Campbell and Michael Douglass

Should Investors Toss in the Towel on Amarin Corp Plc?

Awash with possibilities a decade ago, Amarin ultimately fell as low as $1 per share; tune in to find out what happened.

Mar 26, 2015 by Todd Campbell

3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy?

Esperion Therapeutics, Inc, Novavax, Inc., and Ziopharm are all seeing their shares drop sharply this week.

Mar 25, 2015 by Todd Campbell

Why Ziopharm Oncology, Inc. Shares Burst Today.

Ziopharm Oncology Inc.'s shares are retreating following a more than doubling since January.

Mar 25, 2015 by Todd Campbell

Bubble Bursting? 3 Top Stock Biotech Stocks to Buy

If biotech stocks fall, long-term investors can consider Celgene Corp., Gilead Sciences Inc., and Biogen Inc. for their portfolios.

Mar 25, 2015 by Todd Campbell

Why Esperion Therapeutics, Inc. Shares Burst Today.

After more than doubling, Esperion Therapeutics, Inc. shares are tumbling following the completion of a secondary offering yesterday.

Mar 25, 2015 by Todd Campbell

This Tiny Biotech Offers Up New Hope for Parkinson's Disease Patients

Phase 1 trial results for Prothena Corporation's PRX-002 could indicate that this drug may help treat Parkinson's disease someday.

Mar 24, 2015 by Todd Campbell

Why Abiomed, Inc. is Soaring Higher Today

Abiomed Inc. won approval for another new cardiovascular surgery device.

Mar 24, 2015 by Todd Campbell

Why OvaScience Inc. is Sky-rocketing Higher Today

OvaScience Inc. shares are jumping on hopes that the company can revolutionize in vitro fertilization.

Mar 24, 2015 by Todd Campbell

In Case You Missed It, This Tiny Biotech Is Poised for Explosive Growth

Amicus Therapeutics, Inc. plans to file its drug for Fabry disease with EU and U.S. regulators soon.

Mar 23, 2015 by Todd Campbell

Why ImmunoGen Inc. is Soaring Higher Today

Takeda Pharmaceutical has licensed ImmunoGen's antibody-drug conjugate technology.

Mar 22, 2015 by Todd Campbell

Biotech Stocks: 2 to Avoid, 1 to Buy

Motley Fool contributor Todd Campbell offers insight on three biotech stocks, including two that investors should stay away from.

Mar 22, 2015 by Todd Campbell

3 Things You Need to Know About Achillion Pharmaceuticals Inc.

Achillion Pharmaceuticals has a big opportunity in hepatitis C, but it also faces some risks.

Mar 22, 2015 by Todd Campbell

1 Tiny Biotech's Blockbuster Opportunity in Heart Disease

Esperion Therapeutics Inc. is developing a new cholesterol-busting drug that put up solid results in midstage trials.

Mar 21, 2015 by Todd Campbell

Dividend Stocks: 2 to Avoid, 1 to Buy

Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.

Mar 21, 2015 by Todd Campbell and Michael Douglass

Drug Spending Is Soaring: 3 Takeaways You Can't Miss

Drug spending in the U.S. showed solid growth in several major indications; here’s what it means to you.

Mar 21, 2015 by Todd Campbell

This is Why Diabetes Treatment Costs Are Soaring

A new class of diabetes drugs is driving up the cost of diabetes medicine.

Mar 20, 2015 by Todd Campbell

Why Prothena Corporation Plc is Soaring Higher Today

Results for Prothena's early-stage Parkinson's disease drug, PRX-002, have sent shares surging.

Mar 19, 2015 by Todd Campbell

Why Juno Therapeutics Inc is Soaring Higher Today

Juno Therapeutics Inc.'s fourth quarter earnings did little to dent investor enthusiasm for its cancer research.

Mar 19, 2015 by Todd Campbell

Why Esperion Therapeutics, Inc. is Sky-Rocketing Higher

Esperion Therapeutics, Inc. is raising money to fund development of its cholesterol lowering drug ETC-1002.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services